Literature DB >> 26439800

Sustained Epigenetic Drug Delivery Depletes Cholesterol-Sphingomyelin Rafts from Resistant Breast Cancer Cells, Influencing Biophysical Characteristics of Membrane Lipids.

Vijay Raghavan1, Sivakumar Vijayaraghavalu1, Chiranjeevi Peetla1, Masayoshi Yamada1, Megan Morisada1, Vinod Labhasetwar1,2.   

Abstract

Cell-membrane lipid composition can greatly influence biophysical properties of cell membranes, affecting various cellular functions. We previously showed that lipid synthesis becomes altered in the membranes of resistant breast cancer cells (MCF-7/ADR); they form a more rigid, hydrophobic lipid monolayer than do sensitive cell membranes (MCF-7). These changes in membrane lipids of resistant cells, attributed to epigenetic aberration, significantly affected drug transport and endocytic function, thus impacting the efficacy of anticancer drugs. The present study's objective was to determine the effects of the epigenetic drug, 5-aza-2'-deoxycytidine (DAC), delivered in sustained-release nanogels (DAC-NGs), on the composition and biophysical properties of membrane lipids of resistant cells. Resistant and sensitive cells were treated with DAC in solution (DAC-sol) or DAC-NGs, and cell-membrane lipids were isolated and analyzed for lipid composition and biophysical properties. In resistant cells, we found increased formation of cholesterol-sphingomyelin (CHOL-SM) rafts with culturing time, whereas DAC treatment reduced their formation. In general, the effect of DAC-NGs was greater in changing the lipid composition than with DAC-sol. DAC treatment also caused a rise in levels of certain phospholipids and neutral lipids known to increase membrane fluidity, while reducing the levels of certain lipids known to increase membrane rigidity. Isotherm data showed increased lipid membrane fluidity following DAC treatment, attributed to decrease levels of CHOL-SM rafts (lamellar beta [Lβ] structures or ordered gel) and a corresponding increase in lipids that form lamellar alpha-structures (Lα, liquid crystalline phase). Sensitive cells showed marginal or insignificant changes in lipid profile following DAC-treatment, suggesting that epigenetic changes affecting lipid biosynthesis are more specific to resistant cells. Since membrane fluidity plays a major role in drug transport and endocytic function, treatment of resistant cells with epigenetic drugs with altered lipid profile could facilitate anticancer drug transport to overcome acquired drug resistance in a combination therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26439800      PMCID: PMC4725703          DOI: 10.1021/acs.langmuir.5b02601

Source DB:  PubMed          Journal:  Langmuir        ISSN: 0743-7463            Impact factor:   3.882


  49 in total

Review 1.  Lipid polymorphisms and membrane shape.

Authors:  Vadim A Frolov; Anna V Shnyrova; Joshua Zimmerberg
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-11-01       Impact factor: 10.005

2.  Effects of dose and duration of exposure on 5-aza-2'-deoxycytidine cytotoxicity for L1210 leukemia in vitro.

Authors:  J M Covey; D S Zaharko
Journal:  Cancer Treat Rep       Date:  1984-12

3.  Plasma membrane lipid composition of vinblastine sensitive and resistant human leukaemic lymphoblasts.

Authors:  G L May; L C Wright; M Dyne; W B Mackinnon; R M Fox; C E Mountford
Journal:  Int J Cancer       Date:  1988-11-15       Impact factor: 7.396

4.  Lipid polymorphism and the roles of lipids in membranes.

Authors:  P R Cullis; M J Hope; C P Tilcock
Journal:  Chem Phys Lipids       Date:  1986 Jun-Jul       Impact factor: 3.329

5.  Differences in lipid composition of doxorubicin-sensitive and -resistant P388 cells.

Authors:  A Ramu; D Glaubiger; H Weintraub
Journal:  Cancer Treat Rep       Date:  1984-04

6.  An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line.

Authors:  Maria-Ana Ghetie; Radu Marches; Stephanie Kufert; Ellen S Vitetta
Journal:  Blood       Date:  2004-03-04       Impact factor: 22.113

7.  Effect of verapamil and other agents on the distribution of anthracyclines and on reversal of drug resistance.

Authors:  A A Hindenburg; M A Baker; E Gleyzer; V J Stewart; N Case; R N Taub
Journal:  Cancer Res       Date:  1987-03-01       Impact factor: 12.701

Review 8.  Lipid polymorphism and the functional roles of lipids in biological membranes.

Authors:  P R Cullis; B de Kruijff
Journal:  Biochim Biophys Acta       Date:  1979-12-20

9.  Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells.

Authors:  Joachim Troost; Heike Lindenmaier; Walter Emil Haefeli; Johanna Weiss
Journal:  Mol Pharmacol       Date:  2004-08-12       Impact factor: 4.436

10.  Plasma membrane lipid structural order in doxorubicin-sensitive and -resistant P388 cells.

Authors:  A Ramu; D Glaubiger; I T Magrath; A Joshi
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

View more
  4 in total

Review 1.  Omega-3 fatty acids, membrane remodeling and cancer prevention.

Authors:  Natividad R Fuentes; Eunjoo Kim; Yang-Yi Fan; Robert S Chapkin
Journal:  Mol Aspects Med       Date:  2018-04-12

2.  Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells.

Authors:  Sivakumar Vijayaraghavalu; Vinod Labhasetwar
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

3.  Mesoporous silica nanoparticles functionalized with folic acid/methionine for active targeted delivery of docetaxel.

Authors:  Pegah Khosravian; Mehdi Shafiee Ardestani; Mehdi Khoobi; Seyed Naser Ostad; Farid Abedin Dorkoosh; Hamid Akbari Javar; Massoud Amanlou
Journal:  Onco Targets Ther       Date:  2016-12-01       Impact factor: 4.147

Review 4.  The UDP-glucose ceramide glycosyltransferase (UGCG) and the link to multidrug resistance protein 1 (MDR1).

Authors:  Marthe-Susanna Wegner; Lisa Gruber; Peter Mattjus; Gerd Geisslinger; Sabine Grösch
Journal:  BMC Cancer       Date:  2018-02-06       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.